Suppr超能文献

转化生长因子及其受体水平低效是导致老年成为阿尔茨海默病风险因素的原因。

Ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease.

作者信息

Fessel Jeffrey

机构信息

Emeritus, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.

出版信息

Alzheimers Dement (N Y). 2019 Dec 9;5:899-905. doi: 10.1016/j.trci.2019.11.007. eCollection 2019.

Abstract

After the midninth decade of age, the incidence rates of Alzheimer's disease (AD) and the presence of active TGF-β1 show comparable increases. The hypothesis is proposed that the reason why advanced age is a major risk factor for AD is a progressive decrease with advancing age in the numbers of TGFR2 receptors in the brain, with the consequence of a decline in the neurotrophic efficacy of TGF-β1 and 2 despite their already increased levels in older persons. Alternative, possible reasons are discussed but rejected because either those reasons may also affect young persons or because they cannot be validated in a clinical trial. The proposed hypothesis may be validated in persons with aMCI after raising their brain levels of TGF-β1 and 2 by using a combination of three drugs, lithium, memantine, plus either glatiramer or venlafaxine, and then assessing their progression to AD.

摘要

在90岁中期之后,阿尔茨海默病(AD)的发病率和活性转化生长因子-β1(TGF-β1)的出现呈现出类似的增长。有人提出假说,高龄成为AD主要风险因素的原因是随着年龄增长,大脑中TGFR2受体数量逐渐减少,其结果是尽管老年人中TGF-β1和TGF-β2水平已经升高,但它们的神经营养功效仍会下降。文中还讨论了其他可能的原因,但均被排除,因为这些原因要么也会影响年轻人,要么无法在临床试验中得到验证。通过联合使用三种药物(锂盐、美金刚,再加格拉替雷或文拉法辛)提高轻度认知障碍(aMCI)患者大脑中TGF-β1和TGF-β2的水平,然后评估他们向AD的进展情况,所提出的假说可能会在这些患者中得到验证。

相似文献

1
Ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease.
Alzheimers Dement (N Y). 2019 Dec 9;5:899-905. doi: 10.1016/j.trci.2019.11.007. eCollection 2019.
2
The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression.
Eur Neuropsychopharmacol. 2012 Apr;22(4):281-9. doi: 10.1016/j.euroneuro.2011.08.006. Epub 2011 Sep 15.
3
Decreased serum levels of the angiogenic factors VEGF and TGF-β1 in Alzheimer's disease and amnestic mild cognitive impairment.
Neurosci Lett. 2013 Aug 29;550:60-3. doi: 10.1016/j.neulet.2013.06.031. Epub 2013 Jul 1.
4
Neurobiological links between depression and AD: The role of TGF-β1 signaling as a new pharmacological target.
Pharmacol Res. 2018 Apr;130:374-384. doi: 10.1016/j.phrs.2018.02.007. Epub 2018 Feb 10.
7
Serum levels and genetic variation of TGF-beta1 are not associated with Alzheimer's disease.
Acta Neurol Scand. 2007 Dec;116(6):409-12. doi: 10.1111/j.1600-0404.2007.00892.x.
8
Protection of TGF-β1 against neuroinflammation and neurodegeneration in Aβ1-42-induced Alzheimer's disease model rats.
PLoS One. 2015 Feb 6;10(2):e0116549. doi: 10.1371/journal.pone.0116549. eCollection 2015.
9
Dysfunction of TGF-β1 signaling in Alzheimer's disease: perspectives for neuroprotection.
Cell Tissue Res. 2012 Jan;347(1):291-301. doi: 10.1007/s00441-011-1230-6. Epub 2011 Aug 31.
10
Prevention of Alzheimer's disease by treating mild cognitive impairment with combinations chosen from eight available drugs.
Alzheimers Dement (N Y). 2019 Nov 16;5:780-788. doi: 10.1016/j.trci.2019.09.019. eCollection 2019.

引用本文的文献

2
Emerging Vistas for the Nutraceutical in Inflammaging.
Pharmaceuticals (Basel). 2024 May 7;17(5):597. doi: 10.3390/ph17050597.
3
Formulating Treatment to Cure Alzheimer's Dementia: Approach #2.
Int J Mol Sci. 2024 Mar 20;25(6):3524. doi: 10.3390/ijms25063524.
5
Matrix disequilibrium in Alzheimer's disease and conditions that increase Alzheimer's disease risk.
Front Neurosci. 2023 May 26;17:1188065. doi: 10.3389/fnins.2023.1188065. eCollection 2023.
6
TGF-β1 signalling in Alzheimer's pathology and cytoskeletal reorganization: a specialized Tau perspective.
J Neuroinflammation. 2023 Mar 13;20(1):72. doi: 10.1186/s12974-023-02751-8.
7
TGF-β as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications.
Biomedicines. 2022 May 23;10(5):1206. doi: 10.3390/biomedicines10051206.
9
Mitochondrially-Targeted Therapeutic Strategies for Alzheimer's Disease.
Curr Alzheimer Res. 2021;18(10):753-771. doi: 10.2174/1567205018666211208125855.
10
Caveolae, CD109, and endothelial cells as targets for treating Alzheimer's disease.
Alzheimers Dement (N Y). 2020 Sep 13;6(1):e12066. doi: 10.1002/trc2.12066. eCollection 2020.

本文引用的文献

2
Systematic Review of miRNA as Biomarkers in Alzheimer's Disease.
Mol Neurobiol. 2019 Sep;56(9):6156-6167. doi: 10.1007/s12035-019-1500-y. Epub 2019 Feb 8.
4
Concordance of Several Subcellular Interactions Initiates Alzheimer's Dementia: Their Reversal Requires Combination Treatment.
Am J Alzheimers Dis Other Demen. 2017 May;32(3):166-181. doi: 10.1177/1533317517698790. Epub 2017 Mar 17.
5
Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy.
J Mol Psychiatry. 2016 Jul 15;4:3. doi: 10.1186/s40303-016-0018-8. eCollection 2016.
6
7
Meta-analysis of Telomere Length in Alzheimer's Disease.
J Gerontol A Biol Sci Med Sci. 2016 Aug;71(8):1069-73. doi: 10.1093/gerona/glw053. Epub 2016 Apr 18.
8
Venlafaxine treatment after endothelin-1-induced cortical stroke modulates growth factor expression and reduces tissue damage in rats.
Neuropharmacology. 2016 Aug;107:131-145. doi: 10.1016/j.neuropharm.2016.03.011. Epub 2016 Mar 8.
9
Microglial cell dysregulation in brain aging and neurodegeneration.
Front Aging Neurosci. 2015 Jul 20;7:124. doi: 10.3389/fnagi.2015.00124. eCollection 2015.
10
TGF-beta signalling in the adult neurogenic niche promotes stem cell quiescence as well as generation of new neurons.
J Cell Mol Med. 2014 Jul;18(7):1444-59. doi: 10.1111/jcmm.12298. Epub 2014 Apr 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验